Clinical Trials Logo
  1. Home
  2. Advanced Melanoma
  3. NCT02994498

Safety and Efficacy of DCB-BO1301 in Advanced Melanoma

Advanced Melanoma Clinical Trial

Official title:
An Open-Label Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of DCB-BO1301 as Add-on Therapy to Dacarbazine in Subjects With Advanced Melanoma

Clinical Trial Summary

The primary study objectives are 1. to evaluate the safety and tolerability profiles of DCB-BO1301 and to determine the maximum tolerated dose (MTD) of DCB-BO1301 as add-on therapy to dacarbazine in subjects with advanced melanoma (Phase I) 2. to evaluate the efficacy profile of DCB-BO1301 at MTD or lower dose level as add-on therapy to dacarbazine in subjects with advanced melanoma in terms of progression free survival (Phase IIa)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02994498
Study type Interventional
Source Chung Mei Biopharma Co., Ltd
Contact Leon YZ Zhan, MS
Phone +886-4-2329-0578
Email Leon.Zhan@cm-biopha.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date March 2023
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Terminated NCT04894994 - FLX475 in Combination With Ipilimumab in Advanced Melanoma Phase 2
Completed NCT01621490 - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma Phase 1
Recruiting NCT05098184 - Study on TIL for the Treatment of Advanced Melanoma Early Phase 1
Completed NCT02177110 - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Completed NCT00197912 - Dendritic Cell Based Therapy of Malignant Melanoma Phase 1/Phase 2
Completed NCT04165967 - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma Phase 1
Recruiting NCT04495257 - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Phase 1
Recruiting NCT05968690 - Naltrexone and Propranolol Combined With Immunotherapy Phase 1
Active, not recruiting NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05105100 - Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Completed NCT02171286 - The Oncopanel Pilot (TOP) Study N/A
Terminated NCT01453361 - Phase II FANG™ in Advanced Melanoma Phase 2
Recruiting NCT05120024 - Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Active, not recruiting NCT04951583 - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma Phase 2
Recruiting NCT06112808 - A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin Phase 1
Recruiting NCT01614301 - Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma Phase 1/Phase 2
Recruiting NCT04640545 - A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma Phase 1
Not yet recruiting NCT05629546 - Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors Phase 1